| Title |
Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin
|
|---|---|
| Published in |
Methods in Cell Science, April 2015
|
| DOI | 10.1007/s10616-015-9879-4 |
| Pubmed ID | |
| Authors |
Goran Gajski, Tamara Čimbora-Zovko, Sanjica Rak, Maja Osmak, Vera Garaj-Vrhovac |
| Abstract |
Cisplatin (cDDP) is one of the most widely used anticancer-drugs in both therapy and research. However, cDDP-resistance is the greatest obstacle for the successful treatment of cancer patients. In the present study, the possible joint anticancer effect of bee venom (BV), as a natural toxin, and cDDP towards human glioblastoma A1235 cells was evaluated. Treatment with BV alone in concentrations of 2.5-30 μg/ml displayed dose-dependent cytotoxicity towards A1235 cells, as evaluated with different cytotoxicity assays (MTT, Cristal violet and Trypan blue exclusion assay), with an IC50 value of 22.57 μg/ml based on the MTT results. Furthermore, BV treatment induced necrosis, which was confirmed by typical morphological features and fast staining with ethidium-bromide dye. Pre-treatment with BV induced cell sensitization to cDDP, indicating that BV could improve the killing effect of selected cells when combined with cDDP. The isobologram method used to determine the extent of synergism in combining two agents to examine their possible therapeutic effect showed that combined treatment induced an additive and/or synergistic effect towards selected cells depending on the concentration of both. Hence, a greater anticancer effect could be triggered if BV was used in the course of chemotherapy. The obtained results indicate that joint treatment with BV could be useful from the point of minimizing the cDDP concentration during chemotherapy, thus reducing and/or postponing the development of drug resistance. Our data, in accordance with previously reported results, suggests that BV could be used in the development of a new strategy for cancer treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | 3% |
| Sweden | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 26 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 24% |
| Student > Ph. D. Student | 5 | 17% |
| Student > Bachelor | 3 | 10% |
| Student > Master | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 8 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 28% |
| Agricultural and Biological Sciences | 4 | 14% |
| Chemistry | 3 | 10% |
| Medicine and Dentistry | 2 | 7% |
| Neuroscience | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 11 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2015.
All research outputs
#22,945,287
of 25,584,565 outputs
Outputs from Methods in Cell Science
#910
of 1,028 outputs
Outputs of similar age
#240,175
of 279,707 outputs
Outputs of similar age from Methods in Cell Science
#9
of 10 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,028 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,707 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one.